[go: up one dir, main page]

MX2015005098A - Inhibidores de proteasa flavivirus. - Google Patents

Inhibidores de proteasa flavivirus.

Info

Publication number
MX2015005098A
MX2015005098A MX2015005098A MX2015005098A MX2015005098A MX 2015005098 A MX2015005098 A MX 2015005098A MX 2015005098 A MX2015005098 A MX 2015005098A MX 2015005098 A MX2015005098 A MX 2015005098A MX 2015005098 A MX2015005098 A MX 2015005098A
Authority
MX
Mexico
Prior art keywords
flavivirus
methods
protease inhibitors
treating
subject
Prior art date
Application number
MX2015005098A
Other languages
English (en)
Inventor
Radhakrishnan Padmanabhan
Tadahisa Teramoto
Mark Manzano
Original Assignee
Univ Georgetown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgetown filed Critical Univ Georgetown
Publication of MX2015005098A publication Critical patent/MX2015005098A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan métodos para tratar o prevenir una infección por Flavívirus en un sujeto. Los métodos comprenden administrar al sujeto una cantidad terapéuticamente efectiva de un inhibidor de Flavivirus, por ejemplo, un inhibidor de proteasa Flavivirus. Estos métodos son útiles al tratar y/o prevenir infecciones por Flavivirus tales como, por ejemplo, virus del Nilo Occidental, Virus del dengue, y virus de la encefalitis Japonesa. También se proporcionan métodos para inhibir la proteasa Flavivirus en una célula.
MX2015005098A 2012-10-23 2013-10-23 Inhibidores de proteasa flavivirus. MX2015005098A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261717221P 2012-10-23 2012-10-23
PCT/US2013/066380 WO2014066502A2 (en) 2012-10-23 2013-10-23 Flavivirus protease inhibitors

Publications (1)

Publication Number Publication Date
MX2015005098A true MX2015005098A (es) 2015-09-25

Family

ID=50545466

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005098A MX2015005098A (es) 2012-10-23 2013-10-23 Inhibidores de proteasa flavivirus.

Country Status (4)

Country Link
US (1) US10471082B2 (es)
BR (1) BR112015009128A2 (es)
MX (1) MX2015005098A (es)
WO (1) WO2014066502A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201508374SA (en) 2013-04-16 2015-11-27 Univ Monash Method of viral inhibition
CN110898043B (zh) * 2019-10-25 2023-01-17 南方医科大学 (3,4-二羟基-5-硝基苯基)-(4-甲基苯基)甲酮的医药用途
CN113876755A (zh) * 2021-09-23 2022-01-04 天津国际生物医药联合研究院 阿伐麦布在抗圣路易斯脑炎病毒感染中的潜在应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006132681A2 (en) 2005-02-07 2006-12-14 Irm Llc Methods for identifying compounds that inhibit hiv infection
CN106279283A (zh) 2007-08-13 2017-01-04 症变治疗公司 新颖的葡糖激酶活化剂
WO2010039538A2 (en) * 2008-09-23 2010-04-08 Georgetown University Flavivirus inhibitors and methods for their use
AP3069A (en) 2009-02-27 2014-12-31 Siga Technologies Inc Thienopyridine derivatives for the treatment and prvention of dengue virus infection
WO2010141738A2 (en) 2009-06-03 2010-12-09 President And Fellows Of Harvard College Compositions and method for inhibiting tumor growth

Also Published As

Publication number Publication date
BR112015009128A2 (pt) 2017-07-04
US20150272976A1 (en) 2015-10-01
WO2014066502A2 (en) 2014-05-01
US10471082B2 (en) 2019-11-12
WO2014066502A3 (en) 2014-07-03

Similar Documents

Publication Publication Date Title
CL2018000515A1 (es) Virus de la enfermedad de newcastle y usos de los mismos (divisional sol. 2532-2015)
CO2018002598A2 (es) Compuestos para modular la expresión de angiotensinógeno, composiciones que los contienen y procesos para su producción
MX370664B (es) Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos.
CO6761335A2 (es) Inhibidores del virus de la hepatitis c
MX2013011721A (es) Metodos para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2.
CL2016000805A1 (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
ECSP14013315A (es) Inhibidores de aplicación viral
MX2016000271A (es) Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r.
EA201492188A1 (ru) Макроциклические ингибиторы вирусов flaviviridae
CR20160308A (es) Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores
MX2016004492A (es) Inhibidores de la replicacion del virus de inmunodeficiencia humana (vih).
EA201590703A1 (ru) Ингибиторы mek при лечении вирусных заболеваний
NI201400111A (es) Tratamiento del cáncer con inhibidores tor cinasa
UY36708A (es) MODULADORES DE ROR GAMMA (RORy)
UY34066A (es) Inhibidores del virus de la hepatitis c
MX389999B (es) Estabilizadores de mastocitos para el tratamiento de hipercitoquinemia e infeccion viral
CL2017002913A1 (es) Tratamiento de la hipoglucemia posbariátrica con exendina (9-39)
MX2015003701A (es) Composiciones para tratamiento.
CR20160178A (es) Derivados de desoxinojirimicina y sus métodos de uso
MX2018004243A (es) Regimenes de dosificacion.
UY35328A (es) Tratamiento de formas progresivas de esclerosis múltiple con laquinimod
MX385774B (es) Composiciones para usarse en el tratamiento de una infección activa por mycobacterium tuberculosis.
GT201300267A (es) Isoxazolinas como agentes terapéuticos
MY185108A (en) Method for treatment of labor arrest
BR112014016803A2 (pt) amidas macrocíclicas como inibidoras de protease